Research programme: N-type calcium channel antagonists - Neuromed/Merck

Drug Profile

Research programme: N-type calcium channel antagonists - Neuromed/Merck

Latest Information Update: 16 Jun 2009

Price : $50

At a glance

  • Originator Neuromed Pharmaceuticals
  • Developer Merck & Co; Neuromed Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action N type calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Pain

Most Recent Events

  • 16 Jun 2009 Discontinued - Preclinical for Pain in Canada (PO)
  • 25 Mar 2008 Preclinical development is ongoing
  • 08 Aug 2007 Preclinical development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top